Merit Medical Beats Earnings Expectations and Raises Guidance

MMSI beat second-quarter expectations and raised full-year guidance on both lines, lifting its 2026 revenue range to $1.631 billion to $1.643 billion from $1.612 billion to $1.634 billion, and non-GAAP EPS to $4.25 to $4.35 from $4.01 to $4.15. Raising both revenue and margin guidance in the same quarter is the harder version of a guidance increase.

The operating detail behind it is organic growth accelerating to 9% on a constant-currency basis, the strongest in three years. That acceleration matters more than the headline beat because Merit Medical has historically grown through acquisition, and organic acceleration suggests the existing product portfolio is gaining share rather than the growth being bought.

Merit sells single-use interventional devices into cardiology, radiology, and endoscopy, a category tied to procedure volumes rather than capital equipment budgets. That gives the revenue base more resilience than a hospital capex-linked business, but it also caps the growth ceiling to procedure volume growth plus share gains.

What to watch: whether the 9% organic rate holds against tougher second-half comparisons, gross margin progression as the guidance raise implies operating leverage, and any change in the acquisition cadence, since a company growing organically at 9% faces less pressure to buy growth and can let the balance sheet deleverage instead.

Related Stocks

• MMSI